Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC

Dr Renu Eapen speaks to ecancer about her talk at EAU 2023 regarding the LuTectomy study.
LuTectomy is a prospective study of dosimetry, safety and potential benefit of upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with high-risk localised prostate cancer.
She discusses the background and results of the study.
Dr Eapen talks about how this can be game changing for the treatment of patients with high-risk localised prostate cancer.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php